Welcome to our dedicated page for Galera Therapeutics news (Ticker: GRTX), a resource for investors and traders seeking the latest updates and insights on Galera Therapeutics stock.
Galera Therapeutics, Inc. (GRTX) generates news that reflects the evolution of a clinical-stage biopharmaceutical company navigating complex oncology development and corporate transitions. Company press releases cover clinical trial updates, FDA regulatory interactions, strategic reviews, financing events, corporate restructuring, acquisitions, and asset sales.
Historically, Galera’s news has focused on its superoxide dismutase mimetic programs, including avasopasem manganese for radiotherapy-induced and cisplatin-related toxicities and rucosopasem manganese for use with stereotactic body radiation therapy in non-small cell lung cancer and locally advanced pancreatic cancer. Updates have included the FDA’s acceptance and priority review of the avasopasem New Drug Application, issuance of a Complete Response Letter, scheduling and outcomes of a Type A meeting, and decisions to halt the GRECO-1 and GRECO-2 trials following a futility analysis.
Financial result announcements provide context on research and development spending, general and administrative expenses, net losses, and cash runway expectations, alongside descriptions of workforce reductions and cost-saving measures. These releases also describe the engagement of financial advisors and the Board’s evaluation of strategic alternatives aimed at maximizing stockholder value, including potential mergers, asset sales, licensing arrangements, or dissolution.
More recent news highlights major corporate events such as the Board’s approval of a Plan of Liquidation and Dissolution, the adoption of a limited duration stockholder rights agreement, the acquisition of Nova Pharmaceuticals, Inc., and the subsequent asset purchase agreement with Biossil Inc. for Galera’s dismutase mimetics portfolio. In parallel, Galera’s communications describe a shift toward a pan-nitric oxide synthase inhibitor program in advanced breast cancer.
Investors and observers can use the GRTX news feed to follow developments in Galera’s clinical programs, regulatory milestones, strategic transactions, and capital structure decisions over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Galera Therapeutics (Nasdaq: GRTX) announced a significant finding from the Phase 3 ROMAN trial that focuses on reductions in cisplatin-related chronic kidney disease (CKD) in patients with head and neck cancer. This analysis will be presented at the 2023 ASCO Annual Meeting scheduled for June 2-6, 2023 in Chicago, IL. The presentation, titled One-year reductions in CKD in patients with HNC cancer treated with avasopasem manganese, is set for June 5, 2023, from 1:15 PM to 4:15 PM ET. Avasopasem is currently under priority review by the FDA for severe oral mucositis, with a decision expected by August 9, 2023.
Galera Therapeutics, Inc. (Nasdaq: GRTX) announced a net treatment benefit analysis of the Phase 3 ROMAN trial results at the 10th ECHNO conference in Lisbon, Portugal, highlighting its drug avasopasem manganese's impact on severe oral mucositis (SOM) in head and neck cancer patients. The company’s New Drug Application (NDA) for avasopasem is currently under priority review by the FDA with a PDUFA date set for August 9, 2023. Galera is in discussions with European regulatory authorities for potential approval in Europe, emphasizing the drug's first-in-class potential to improve patient quality of life following radiotherapy.
Galera Therapeutics (GRTX) announced a pivotal year ahead with FDA's Priority Review for its NDA on avasopasem, aimed at reducing radiotherapy-induced severe oral mucositis (SOM) in head and neck cancer patients. The PDUFA target date is set for August 9, 2023. The company raised $30 million through a direct offering to support operations and upcoming commercial efforts. Financially, Q4 2022 showed research and development expenses of $8.1 million, with a net loss narrowing to $(16.2) million. For the entire year, 2022's net loss was $(62.2) million, a significant improvement from $(80.5) million in 2021.